Last updated: 2026-09-05 13:19:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Ovid Therapeutics Inc. (OVID) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.80, with a market capitalization of $529.26M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.12 to $3.11. This page covers its latest market performance, valuation, price trends and company information.
$529.26M | |
$2.74 | |
$15.93 | |
$0.24 | |
$2.78 | |
956.76K | |
-- | |
-- | |
$3.11 | |
$1.12 | |
-- | |
-- |
Ovid Therapeutics Inc. (OVID) last closed at $2.78 as of 2026-09-04 23:35:00, unchanged from the previous close of $2.78.
During the latest regular trading session, OVID traded between $0.24 and $15.93, with a volume of 956.76K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Ovid Therapeutics Inc. (OVID) moved from $2.78 to $2.80, representing a gain of 0.54% ($0.02).
The stock traded between $2.71 and $2.82 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 1.44 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 84.4%
OVID is currently trading at $2.80, placing it 84.4% of the way from its 52-week low of $1.12 to its 52-week high of $3.11. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 23 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Ovid Therapeutics Inc. (OVID) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.